Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous
agents, but the risk often only becomes apparent after the marketing authorisation of such …

Mammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive
agents in solid-organ transplant recipients (everolimus and sirolimus) and as antineoplastic …

Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed
death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical …

Introduction Effective treatments for hormone-receptor-positive (HR+) breast cancer (BC)
following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are …

Use of molecular targeting agents and immune checkpoint inhibitors (ICIs) has increased
the frequency and broadened the spectrum of lung toxicity, particularly in patients with …

Consensus statement for the diagnosis and treatment of drug-induced lung injuries. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu …

With the advent of targeted agents for the treatment of renal cell carcinoma (RCC), overall
survival has improved, and patients are being treated continuously for increasingly long …

Background Tuberous sclerosis (TSC) related tumors are characterized by constitutively
activated mTOR signaling due to mutations in TSC1 or TSC2. Methods We completed a …

The mTOR signaling pathway is dysregulated in∼ 50% of all human malignancies and is a
major cancer drug target. Although rapamycin analogs (rapalogs) have shown clinical …

Introduction: Mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus)
are a class of immunosuppressive drugs approved for solid organ transplantation (SOT). By …